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Objective: Surgical knee joint distraction (KJD) leads to clinical improvement in knee osteoarthritis (OA)
and also apparent cartilage regeneration by magnetic resonance imaging. We investigated if alteration of
the joint's mechanical environment during the 6 week period of KJD was associated with a molecular
response in synovial ﬂuid, and if any change was associated with clinical response.
Method: 20 individuals undergoing KJD for symptomatic radiographic knee OA had SF sampled at
baseline, midpoint and endpoint of distraction (6 weeks). SF supernatants were measured by immu-
noassay for 10 predeﬁned mechanosensitive molecules identiﬁed in our previous pre-clinical studies.
The composite Knee injury and OA Outcome Score-4 (KOOS4) was collected at baseline, 3, 6 and 12
months.
Results: 13/20 (65%) were male with mean age 54±5yrs. All had KellgreneLawrence grade 2 knee OA.
6/10 analytes showed statistically signiﬁcant change in SF over the 6 weeks distraction (activin A; TGFb-
1; MCP-1; IL-6; FGF-2; LTBP2), P < 0.05. Of these, all but activin A increased. Those achieving the min-
imum clinically important difference of 10 points for KOOS4 over 6 months showed greater increases in
FGF-2 and TGFb-1 than non-responders. An increase in IL-8 during the 6 weeks of KJD was associated
with signiﬁcantly greater improvement in KOOS4 over 12 months.
Conclusion: Detectable, signiﬁcant molecular changes are observed in SF following KJD, that are
remarkably consistent between individuals. Preliminary ﬁndings appear to suggest that increases in
some molecules are associated with clinically meaningful responses. Joint distraction may provide a
potential opportunity in the future to deﬁne regenerative biomarker(s) and identify pathways that drive
intrinsic cartilage repair.
© 2020 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Osteoarthritis (OA) affects all joint tissues, with articular carti-
lage loss being one of the hallmarks of progressive disease1. It is
likely that excessive mechanical load or loss of mechano-protective
mechanisms in the joint is an underlying process in many cases of
disease, but that there are other superimposed factors such as
inﬂammation that modify its course2e6. Longitudinal cohorts such
as the Osteoarthritis Initiative and Clinical Assessment of the Knee
(CAS-K) show that in ~40% of individuals with early knee OA, pain
may stabilise or improve over time, suggesting that the diseasemay
remit and is not inevitably progressive7. Interventions that me-
chanically off-load the joint, such as strengthening exercises,
weight loss, orthotics such as bracing or surgical interventions such
as osteotomy or unloading devices all reduce knee symptoms1,8.
It is often stated that adult articular cartilage is unable to repair
but a body of literature is emerging that challenges this concept. This
is best exempliﬁed by traumatic focal cartilage defects that can
repair spontaneously in young joints (reviewed in9), but in in-
dividuals undergoing high tibial or distal femoral osteotomy for OA,
structural modiﬁcation has also been observed10. The other evidence
comes from studies of surgical knee joint distraction (KJD). The
primary goal of this treatment is to improve symptoms sufﬁciently to
delay knee arthroplasty. This is especially the case in younger pa-
tients, since these individuals have an increased risk of revision
arthroplasty11. KJD is a technique where, under anaesthesia, an
external ﬁxation frame is placed on both sides of the joint, allowing
distraction (gradual pulling apart of the joint's bony ends by ~5 mm
for 6weeks). During distraction, the patient is encouraged toweight-
bear on the extended knee. Such weight-bearing creates intermit-
tent joint ﬂuid pressure changes, due to built-in springs in the frame
enabling a maximal 3 mm axial displacement under full body
weight12. Studies of joint distraction have shown sustained and
clinically signiﬁcant improvement at a number of joint sites13,14. For
knee OA, joint distraction improved knee symptoms for 5e9 years in
individuals with established OA15,16. Remarkably, the 6 week inter-
vention also led to apparent cartilage regeneration in the subsequent
months and years, with increase in joint space width on X-ray, and
increased articular cartilage thickness on magnetic resonance im-
aging (MRI)14,16e18. These studies suggest that, by temporarily off-
loading the joint, KJD might somehow be responsible for ‘priming’
the joint to enable intrinsic cartilaginous repair. The biological
mechanisms which underlie such a response are not understood but
may include changes in the peri-articular bone and enhanced
mesenchymal stem cell attachment to the damaged joint sur-
face19,20. KJD is therefore an attractivemechanisticmodel inwhich to
investigate potential reparative pathways and identify novel asso-
ciated markers of clinical response.
Synovial ﬂuid (SF) represents an accessible ﬂuid that contains
molecules reﬂecting biological processes within the joint. These
molecules are joint tissue-agnostic; likely being derived from all
the tissues interfacing the joint cavity and can be sampled
repeatedly to monitor change over time within an individual. SF
may represent joint tissue changes more accurately than mea-
surements from blood or urine21,22. We have previously investi-
gated 7 candidate proteins in the SF of individuals after acute knee
injury. These molecules were originally shown to be induced in
murine knee OA in a highly mechanosensitive manner3. 6 out of 7
proteins were found to be substantially up-regulated in those with
acutely injured knees compared with controls23. These molecules
included interleukin (IL)-6, matrix metalloproteinase (MMP)3 and
monocyte chemoattractant protein (MCP)-1, associated with in-
ﬂammatory activation but also others such as activin A, tumour
necrosis factor-stimulated gene (TSG)-6 or tissue inhibitor of met-
alloproteinases (TIMP)-1, which have purported anti-catabolic/Please cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.oanabolic roles24. Our preclinical work has also identiﬁed candidate
chondro-protective molecules that are released by damaged carti-
lage including FGF-2 and TGFb25e27. Both of these are present in SF
and have roles in chondrogenesis28,29.
We hypothesised that over the course of KJD, changes in the
joint's mechanical environment modulate these candidate SF
markers. We further hypothesised that changes in these mecha-
nosensitive molecules either alone or in combination would be
associated with clinical outcome. We set out to test these hypoth-
eses in a proof-of-concept study in a group of individuals under-
going planned surgical KJD.
Method
Ethics
Approval for this study was given by a research ethics com-
mittee (#15-160/D; NL51539.041.15). Usual care clinical data was
also accessed (#17-005). All participants gave written informed
consent to participate prior to screening, according to the Decla-
ration of Helsinki.
Participants
Potential participants were identiﬁed by the orthopaedic sur-
geon (RC) from a population with knee OA attending for consid-
eration of KJD as part of their usual clinical care at a single site in
Netherlands (University Medical Center Utrecht). Inclusion criteria
were: age<65 years; knee OA fulﬁlling ACR clinical criteria30;
Kellgren and Lawrence (KL) grade2 on X-ray31; knee ligaments
intact; preserved range-of-motion (ﬂexion>120; no loss of full
extension); SF sample available at baseline. Exclusion criteria were:
history of inﬂammatory arthritis affecting the index knee including
rheumatoid arthritis; recent infection or systemic inﬂammatory
disease; post-traumatic ﬁbrosis; tibial plateau fracture; extensive
bone-on-bone contact on X-ray; previous or planned knee arthro-
plasty during study period; surgery to the index knee within last 6
months; primary (isolated) patellofemoral OA; contralateral knee
requiring surgical treatment; inability/contraindication/not con-
senting to provide SF; BMI35 kg/m2; pregnancy.
Clinical outcomes
Knee Injury and Osteoarthritis Outcome Score (KOOS) was
collected as part of usual hospital care electronically at baseline, 3, 6
and 12 months [Fig. 1(A)]. From this, KOOS4, a single composite
score which has been validated as a single outcome in other clinical
studies was calculated (the mean of 4 of 5 KOOS subscales: Pain,
Symptoms, Sports/Recreation and Quality of Life)32,33.
Usual care intervention
A non-hinged, external proof-of-concept ﬁxation joint distrac-
tion frame (Monotube Triax with pin clamps, Stryker) [Fig. 1(B)]
was ﬁtted to the index knee by an orthopaedic surgeon (RC) whilst
the patient was under spinal or general anaesthesia (GA) and the
joint surfaces distracted by 5mm. The framewas thenworn for 6e7
weeks.
Participant biological samples
A maximum of 2 ml of SF was aspirated by needle from the
index knee at baseline visit (whilst participant under anaesthesia
and prior to the distraction frame being ﬁtted), subsequently at
midpoint of distraction (3-4 weeks, under local anaesthesia) and atl ﬂuid changes upon joint distraction and is associated with clinical
rg/10.1016/j.joca.2019.12.005
Fig. 1
Design and outcome measures of a proof-of-concept study to investigate synovial fluid analytes at
time of knee joint distraction. A, Flow chart indicating timings of study visits, collection of synovial ﬂuid
samples and collection of KOOS from 20 participants, including completeness of sampling/data over the 12
month study period. A further 2 participants gave consent but no baseline SF could be aspirated so they
were excluded from further analysis as per protocol. B, Illustration of distraction frame which is surgically
placed on the knee joint for a 6 week period. C, KOOS4 measurements in participants at baseline (pre-
distraction), 3 months, 6 months and 12 months after surgical knee joint distraction. Medians and inter-
quartile ranges are shown (bar and line). Abbreviations: KOOS, Knee Injury and Osteoarthritis Outcome
Score (KOOS4 is composite measure of 4 domains); SF, synovial ﬂuid.
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distraction frame was removed under anaesthesia) [Fig. 1(A)].
Within 2 h, all samples were centrifuged for 20 min at 3000G.
Supernatants were stored in 200 ml aliquots in cryovials at80C in
monitored freezers.
Comparator ranges
Normal: These were calculated in previously collected SF from
patients undergoing amputation for treatment of lower limb
tumour, at Royal National Orthopaedic Hospital (Stanmore), Lon-
don, UK, or transplant donation, at Charing Cross Hospital, London,
UK (REC 09/H0710/60), who had macroscopically normal knee
articular cartilage at the time of surgery and no evidence of arthritis
or tumour invasion into the joint23. OA: These were calculated from
measurements in SF from research tissue bank samples of patients
with a conﬁrmed diagnosis of OA undergoing partial or total joint
replacement surgery at the Nufﬁeld Orthopaedic Centre, Oxford, UK
(REC 09/H0606/11þ5). SF had been processed and stored as above.
Reagents
General laboratory reagents were the best available grade from
either SigmaeAldrich (Dorset, UK) or BDH (Dorset, UK) unlessPlease cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.ootherwise stated. MesoScale Discovery (MSD) plates and MSD
SULFO-TAG labelled Streptavidin (#R32AD-5) were from MSD
(Rockville, MD, USA). Enzyme-linked immunosorbent assays (ELI-
SAs) were from commercial providers (Table I).
Assays
Assays were conducted for 10 pre-deﬁned candidate molecules
listed in Table I. All assays were carried out as per manufacturers’
instructions unless stated otherwise. Each assay had either previ-
ously undergone validation by us23 or else underwent structured
performance assessment and optimisation for SF for this project,
and all also passed quality performance requirements during
sample reads (Table I). ELISA plates were read using Berthold
Mithras LB940 reader and MSD plates by MSD QuickPlex SQ120
reader (analysed with MSD Discovery Workbench software
v4.0.12). For TSG-6, each plate well (MSD, Rockville, USA, L15XA)
was custom-coated with 30 ml 10 mg/ml TSG-6 capture antibody
(Merck, MABT108) in phosphate-buffered saline (PBS) overnight at
4C. Methods were then as described23. Mean concentrations of
analytes were calculated from duplicate assay reads for each
participant for each timepoint. Inter- and intra-assay coefﬁcients of
variation (C.V.s) were calculated for all assays. The lower limit of
quantitation (LLOQ) was calculated for all assays. Where al ﬂuid changes upon joint distraction and is associated with clinical
rg/10.1016/j.joca.2019.12.005
Analyte Assay Manufacturer
(Catalog No.)
Intra-Assay CV Inter-Assay CV Lower Limit of
Normal (SF)
Upper Limit of
Normal (SF)
Diln
Factor (SF)
(%) (%) (pg/ml) (pg/ml)
Activin A Human/Mouse/Rat Activin
A Quantikine ELISA
R&D (DAC00B) 3.9 11.7 1,028 5,253 50
MCP-1 V-PLEX Human MCP-1 MSD (K151NND-1) 3.1 5.1 60 493 5
FGF-2 V-PLEX Human (basic) FGF-2 MSD (K151MDD-1) 4.0 6.1 2 411 4
IL-6 V-PLEX Custom Human Cytokine MSD (K151A0H-1) 4.1 9.7 1 20 5
IL-8 V-PLEX Custom Human Cytokine MSD (K151A0H-1) 3.5 8.9 2 39 5
LTBP2 Human LTBP2 ELISA Abbexa (abx 152242) 6.6 17.3 1,887 13,630 4
MMP3 Human MMP3 Ultra-Sensitive MSD (K151FZC-1) 4.7 13.6 3,742 231,000 50
TGFb-1 Human TGFb-1 Quantikine ELISA R&D (DB100B) 3.7 13.0 257.3 1,545 4
TIMP-1 Human TIMP-1 Ultra-sensitive MSD (K151JFC-1) 9.1 10.3 143,000 744,700 200
TSG-6 In-house, self-coated MSD MSD (L15XA-1) 4.5 7.1 6,479 19,060 6
Inter- and intra-assay coefﬁcients of variation (C.V.s) were calculated for all assays. Lower and upper limits were also calculated for all assays for normal ranges using
the geometric mean ± 2 standard deviations.
Abbreviations: CV -coefﬁcient of variation; Diln -Dilution; MSD Mesoscale Discovery.
Table I Assay characteristics of panel of 10 candidate markers OsteoarthritisandCartilage
Baseline Characteristic N (%), or mean, SD
Sex
Male 13 (65%)
Female 7 (35%)
Age (years) 55, 5
Body Mass Index (BMI) 29, 3
Kellgren and Lawrence grade
2 2 (10%)
3 10 (50%)
4 8 (40%)
KOOS4 30, 11
Abbreviations: SD Standard deviation; KOOS4, Knee injury and OA outcome
score-4.
Table II
Baseline characteristics of
study participants
Osteoarthritis
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Lower and upper limits were also calculated for all assays for
normal ranges using the geometric mean ± 2 standard deviations.
Statistical analysis
All available data were analysed on all participants with sufﬁ-
cient SF at each of the 3 timepoints (and one patient with samples
at baseline and 3weeks). All SF analytes were above LLOQ (allowing
attribution of endpoint measurements) except for one sample each
for TGFb1 at baseline, FGF-2 at midpoint and activin A at endpoint.
These values were considered as 50% of the LLOQ. Sample and KOOS
completeness are shown in Fig. 1(A). Missing data were not
imputed.
Change in KOOS4 over time
Median differences between paired observations of KOOS4 at
baseline and either 3, 6 or 12 months were compared by Wilcoxon
signed rank test.
Change in analyte levels over time
Median differences between paired observations (baseline vs 3
or 6 weeks) of analyte levels were compared by Wilcoxon signed
rank test. Effect size (ES) was reported as the difference between
medians. Correlations between the changes over 6 weeks for each
analyte were assessed by Spearman's R coefﬁcient (range 1 to 1;
where ±1 ¼ strongest positive (or negative) correlation, 0 ¼ no
correlation).
Association of change in analytes with KOOS4
The clinical outcome variable was change in KOOS4 over time
(KOOS4 at either 3, 6 or 12months respectivelyKOOS4 at baseline).
Linear regressionwas employed to model the relationship between
continuous change in analyte levels (concentrations at 6 or 3 weeks
e baseline concentrations) and change in KOOS4.
In a planned secondary analysis, linear regression also assessed
change in KOOS4 by categories of change in analytes. Concentra-
tions of analytes (at baseline and 6 weeks) were classiﬁed into
normal (25th and <75th percentiles), high (75th percentile) andPlease cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.olow (<25th percentile) categories. The 25th and 75th centiles were
calculated from measurements of these molecules in SF from 40
individuals with OAwho had undergone either partial or total knee
joint replacement (see Comparator ranges). These data were
generated at same time as participant data, using the same assay
batches. ‘Relevant change’ was deﬁned as a movement between at
least one category from baseline to 6 weeks (relevant increase, or
relevant decrease), or as no relevant change.
Change in analytes by responders and non-responders in KOOS4
Responders (those whose change in KOOS4 over 6 months (the
latest point at which there was clinical change from baseline),
[Fig. 1(C)] was 10 points, i.e., the minimal clinically important
difference (MICD) for KOOS4)32; and Non-Responders (those whose
KOOS4 change over 6 months was <10 points) were categorized.
Differences between molecular changes in these 2 groups were
compared by Mann-Whitney U test.l ﬂuid changes upon joint distraction and is associated with clinical
rg/10.1016/j.joca.2019.12.005
Fig. 2
Measurement of synovial fluid analytes during knee joint distraction. Synovial ﬂuid from study par-
ticipants immediately prior to distraction (‘baseline’), after 3 weeks of knee joint distraction (‘midpoint’) and
at 6 weeks after knee joint distraction (‘endpoint’) were assayed for pre-deﬁned markers of interest by
electrochemiluminescence or ELISA (see Table I). Measurements for each of 10 analytes are shown, with
mean concentrations for each analyte plotted on a log 10 y axis. *P < 0.05,**P < 0.01,***P < 0.001 by
Wilcoxon signed rank test, comparing paired levels at end point or midpoint vs baseline (individual P values
are given in Supplementary Table 1). A, shows 6 analytes with change at endpoint vs baseline. B, shows 4
analytes without change at endpoint (although upper 2 showed change at midpoint). ULN and LLN of
normal ranges were calculated for each analyte as described in methods and Table I. Abbreviations: LLOQ,
lower limit of quantiﬁcation; ULN, upper limit of normal; LLN, lower limit of normal; LTBP2, latent-trans-
forming growth factor beta-binding protein 2; TGFb-1, transforming growth factor beta 1; FGF-2, basic
ﬁbroblast growth factor; TIMP-1, tissue inhibitor of metalloproteinases 1; TSG-6, tumour necrosis factor-
inducible gene 6 protein; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; IL-8, interleukin 8;
MMP3, matrix metalloproteinase-3.
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was performed in STATA IC 13.1 and Graphpad Prism 6.03.Results
13/20 (65%) participants were male with mean age 55 ± 5 years
(Table II). All had KL grade2; 18 (90%) grade 3/4, with substantial
knee pain at baseline (KOOS pain 38.6 ± 16.0; where 100 is no pain,
normal function). As expected from previously published studies,
there was an improvement in KOOS4 in the subsequent months
following the intervention [Fig. 1(C)].
6/10 SF analytes showed changes between baseline and 6 weeks
(IL-6, ES ¼ 56.6, P ¼ 0.0043; MCP-1, ES ¼ 155.1, P ¼ 0.0016; FGF-2,
ES¼ 164.7, P¼ 0.0123; TGFb-1, ES¼ 2.1, P¼ 0.0003; LTBP2, ES¼ 0.4,
P ¼ 0.0475; activin A, ES ¼ 6.8, P ¼ 0.0002) [Fig. 2(A)] and
(Supplementary Table 1). Of these, IL-6, MCP-1, FGF-2 and TGFb-1
showed a predominant increase in levels, while activin A mainly
decreased (to within normal range for most individuals). There was
variation in response between individuals, exempliﬁed by LTBP-2.
For several analytes, change was detectable within 3 weeks of
distraction (activin A, TGFb-1 and IL-6) (Supplementary Table 1). 2
further molecules, IL-8 and TIMP-1 were different at 3 weeks
(ES ¼ 73.5 and ES ¼ 389, respectively), but not at 6 weeks
(ES ¼ 10.5, ES ¼ 115.2, respectively) [Fig. 2(B)], (upper panels). The
remaining 2 analytes (MMP3, TSG-6) did not change over the
distraction period (ES ¼ 75.3, P ¼ 0.53 and ES ¼ 41,508, P ¼ 0.21
respectively, Fig. 2(B), lower panels).
Several analytes correlated with each other in their change over
the 6 week distraction period (Fig. 3). Associations between
changes in markers could also be seen over the initial 3 weeks of
knee joint distraction (Supplementary Figure 1). Higher correla-
tions were found for TGFb-1 and FGF-2 (R¼ 0.68); IL-6, TIMP-1 and
either MMP3 or TSG-6; (all pairs R > 0.5). LTBP2 and activin A hadFig. 3
Correlation between change of analytes in the synovial
distraction. Spearman rank tests were performed to determ
synovial ﬂuid analytes over the 6 week distraction period
tions). Correlation coefﬁcients were calculated using all
repeated (duplicate) measures for each synovial ﬂuid sam
efﬁcient is shown: * (Mid grey shading): Low positive (nega
(Dark grey shading): Moderate positive (negative) correlatio
LTBP2, latent-transforming growth factor beta-binding pro
1; FGF-2, basic ﬁbroblast growth factor; TIMP-1, tissue in
necrosis factor-inducible gene 6 protein; IL-6, interleukin 6
IL-8, interleukin 8; MMP3, matrix metalloproteinase 3.
Please cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.olow correlationwith other analytes over time. TGFb-1 and IL-6were
negatively correlated (R ¼ 0.43).
The association of change in candidate molecules over the
distraction period with subsequent change in KOOS4 was exam-
ined. Change in 4 molecules was associated with change in KOOS4
over the ﬁrst 3 months: activin A, TGFb-1, FGF-2 and MCP-1
[Fig. 4(A)]. For all except activin A, an increase in the analyte was
associated with greater improvement in KOOS4, but the effects
were weak (Supplementary Table 2). The low effect sizes were
primarily because the unit of change of a marker within the
regression model was per 1 pg/ml, whereas often much larger
changes in markers than 1 pg/ml were seen. Similar associations
persisted at 6 months for all 4 molecules. For example, for the effect
of change in FGF-2 over 6-weeks, on change in KOOS4 over 6-
months, for a 1-unit increase in FGF-2 change per pg/ml, the change
in KOOS4 is 0.03 points. To interpret the 95% CI, the underlying
effect in the population could lie between 0.004 and 0.057. To aid
interpretation, the median increase of FGF-2 over 6 weeks is
165 pg/ml. Hence for a 165 pg/ml unit increase in FGF-2, the change
in KOOS4 is 4.95 points (95%CI 0.66 to 9.41). IL-8 had the largest and
increasing effect size (0.28 by 12 months), but the conﬁdence in-
tervals at all timepoints were wide.
To test the relevance of these ﬁndings, we categorised partici-
pants’ molecular measurements as having no relevant change, a
relevant increase or a relevant decrease over the 6 week distraction
period (see methods) and examined the association of these cate-
gories with change in KOOS4. Those with a relevant increase in SF
IL-8 during the distraction period had a greater improvement in
KOOS4 over 12 months than those with no change (regression co-
efﬁcient 17.6 [1.2, 34.0]; P ¼ 0.04). However, no other molecular
changes were associated with clinical outcomewhen categorised in
this way (Supplementary Table 3). Furthermore, the conﬁdence
intervals for this observation are wide and given that the otherfluid of participants over period of knee joint
ine correlations between the change in levels of
(concentration at 6 weeks-baseline concentra-
available participant data and the mean of 2
ple. Strength of correlation by Spearman R co-
tive) correlation, 0.30 to 0.49 (0.30 to 0.49). **
n, 0.50 to 0.69 (0.50 to 0.69). Abbreviations:
tein 2; TGFb-1, transforming growth factor beta
hibitor of metalloproteinases 1; TSG-6, tumour
; MCP-1, monocyte chemoattractant protein 1;
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Fig. 4
Association of change in synovial fluid analytes with the clinical outcome KOOS4.. A Linear regres-
sion models for the association of the change over the distraction period for each of 10 synovial ﬂuid
analytes (measured in pg/ml) with participants' change in KOOS4 over varying periods are shown: upper
panel, change in KOOS4 over 3 months; middle panel, change in KOOS4 over 6 months and lower panel,
change in KOOS4 over 12 months. Forest Plots of unadjusted (crude) results, including the regression
coefﬁcient for the effect on KOOS4 change over the speciﬁed period and 95% conﬁdence intervals are
shown (data also shown in Supplementary Table 2). B The change of concentration in each analyte over the
6 week distraction period is shown (6 week level e baseline level), for 2 subgroups: Responders (those
whose change in KOOS4 over 6 months was 10 points, i.e., those achieving the MICD for KOOS4); and
Non-Responders (those whose change in KOOS4 over 6 months was <10 points, i.e., those not achieving
the MCID for KOOS4). The bars represent the median and 95% Conﬁdence Intervals for each group. Be-
tween group comparisons were by Mann-Whitney U test, *P ¼ 0.04; ¥P ¼ 0.01. Abbreviations: MCID,
minimal clinically important difference; LTBP2, latent-transforming growth factor beta-binding protein 2;
TGFb-1, transforming growth factor beta 1; FGF-2, basic ﬁbroblast growth factor; TIMP-1, tissue inhibitor of
metalloproteinases 1; TSG-6, tumour necrosis factor-inducible gene 6 protein; IL-6, interleukin 6; MCP-1,
monocyte chemoattractant protein 1; IL-8, interleukin 8; MMP3, matrix metalloproteinase-3; KOOS, Knee
Injury and Osteoarthritis Outcome Score (KOOS4 is composite measure of 4 domains).
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chance ﬁnding).
We also compared the change in analyte levels over the 6 weeks
of distraction in those making the MCID of 10 points or more by
KOOS4 (responders) with those who did not improve by this
amount (non-responders). The clinical response to joint distraction
was most pronounced at 6 months, with 11/15 (73%) of individuals
with available data reaching a MCID on KOOS4. Responders at 6
months had a greater increase in TGFb-1 and FGF-2 during the
distraction period than non-responders [Fig. 4(B)], (Supplementary
Table 4 and Supplementary Figure 2). Similar analyte changes werePlease cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.oalso seen in responders and non-responders at 3 months, when
TIMP-1 levels were also different between the 2 groups
(ES ¼ 497 ng/ml, P ¼ 0.02, Supplementary Figure 3).
Discussion
Easily detectable, substantial changes in levels of 8 putative
mechanosensitive molecules of the inﬂammatory response (activin
A, LTBP2, TGFb-1, FGF-2, TIMP-1, IL-6, MCP-1, and IL-8) were seen in
SF over the period of KJD. There were also associations between
several of these molecules over time. These changes would notl ﬂuid changes upon joint distraction and is associated with clinical
rg/10.1016/j.joca.2019.12.005
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increase, others stay the same or even decrease. Of the regulated
molecules, whilst IL-6 and MCP-1 (also known as CCL-2) have been
associated with degeneration or pain in the osteoarthritic joint34,35,
FGF-2 and TGFb-1 aremore typically associatedwith repair27,36. It is
perhaps not surprising that a mechanically-induced inﬂammatory
response should include both catabolic and reparative processes.
But that an intervention which apparently leads to net articular
cartilage repair involves the activation of traditionally inﬂamma-
tory pathways would go against current convention. Overall there
was substantial variation between individuals for certainmolecules
in the extent and sometimes direction of this response. This sup-
ports the notion that an individual's biological response to the
intervention could vary and be related to their clinical response. On
the other hand, some molecules like TGFb-1 and Activin A showed
very consistent directional changes following KJD.
Our proof-of-concept study appears to suggest an association
between this measurable biological response to joint distraction
and subsequent clinical outcome. The clinical response to joint
distraction was most pronounced at 6 months. Several of the as-
sociations between change in analytes and KOOS4 at 6monthswere
also apparent at 3 and 12 months, and when individuals were
stratiﬁed, either by their molecular response or their clinical
response. This supports that elements of this biological response to
distraction appeared to be associated with a clinically meaningful
response: for example, FGF-2 and TGFb-1, typically associated with
cartilage anabolism/anti-catabolism, were raised in responders37,38.
One molecule, activin A, strikingly fell in all individuals to what
we estimate are normal levels in human SF. Activin A is produced by
osteoarthritic and injured articular cartilage and promotes skin
wound healing39,40. Its direction of change (opposite to that of FGF-
2/TGFb-1) is perhaps surprising: activin A is a TGFb superfamily
member24 and is strongly FGF-2-dependent in the joint in our pre-
clinical studies38,39. It may be that these apparent paradoxes are
because different joint tissues are involved: FGF-2 and TGFb may
derive from the capsule, say, whereas joint-ofﬂoading may reduce
the cartilage injury response, reducing activin A. Whilst activin A
appears to be a highly sensitive read-out of the intervention, it does
not show association with beneﬁt, perhaps because its change is so
consistent.
There are some limitations of this study. It is important to avoid
over-interpretation of what was a small experimental study, and
we have reported conﬁdence intervals of association of change in
molecules with change in KOOS4, to reﬂect the level of certainty. No
correction was made for multiple testing: some apparent associa-
tions could have been found by chance.
Identiﬁcation of truly ‘normal’ individuals or those with OAwho
are of exactly the same demographic and stage of disease and who
are willing to undergo sampling of SF is challenging. Our ‘Normal
comparator’ group included those individuals undergoing surgery
for musculoskeletal tumours, which could potentially have inﬂu-
enced circulating levels of analytes. The OA comparator group was
selected from a bank of samples collected at the time of arthro-
plasty to be as similar as possible in terms of gender and age.
However, it is possible by the nature of the intervention that some
would have had more advanced stage of disease or slight differ-
ences in other factors to those in the Joint Distraction group,
meaning they were not directly comparable. However, the validity
of our ﬁndings do not rely solely on such Comparator data (with
most comparisons made within the cohort of those undergoing
distraction).
These results need to be validated in a larger, independent
study, where potentially relevant additional covariates (such as age,
BMI) and structural imaging outcomes are incorporated13 (Corre-
lation of marker change with imaging-based measures of cartilagePlease cite this article as: Watt FE et al., The molecular proﬁle of synovia
response in knee osteoarthritis, Osteoarthritis and Cartilage, https://doi.othickness or volume in this current small study was not included as
there would have been lack of power to detect an effect). As this
intervention was part of usual care and not a clinical trial, this may
have led to increased missing data and somewhat less striking
improvement in clinical outcomes. This contrasts with previously
published data in KJD suggesting a clinically signiﬁcant long-term
response14,16e18. A comparison between patients treated in clinical
practice and those in (randomised) clinical trials revealed no clear
differences in clinical outcomes between these 2 settings at 12
months (data to be published elsewhere). This study was not
designed to detect a difference in clinical outcome and likely lacked
power to detect differences at 12 months.
In summary, we have shown a measurable molecular response
in SF to joint distraction, which appears to be associated with pa-
tient-reported outcomes. This observation supports the accurate
measurement of this response in SF as both possible and informa-
tive22,41. Ways of ﬁnding associations with a positive outcome to
distraction are currently limited13. These observations show the
potential to deﬁne biomarker(s) associated with positive clinical
responses to this and similar interventions aiming to off-load the
joint surfaces42,43. Biomarker stratiﬁcation, identifying individuals
most likely to respond in clinical trials or usual care would increase
the utility of this already apparently cost-effective intervention44.
Experimental studies of joint distraction represent a novel way of
identifying potential regenerative pathways that drive intrinsic
connective tissue repair; these pathways might be amenable to
augmentation, by pharmacological or other means to treat symp-
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